Cyclerion Operating Income from 2010 to 2024
| CYCN Stock | USD 2.20 0.04 1.85% |
Operating Income | First Reported 2018-03-31 | Previous Quarter -1.4 M | Current Value -1.1 M | Quarterly Volatility 10.9 M |
Check Cyclerion Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cyclerion Therapeutics' main balance sheet or income statement drivers, such as Discontinued Operations of 0.0, Interest Expense of 355 K or Selling General Administrative of 16.2 M, as well as many indicators such as Price To Sales Ratio of 90.71, Dividend Yield of 0.0 or PTB Ratio of 0.73. Cyclerion financial statements analysis is a perfect complement when working with Cyclerion Therapeutics Valuation or Volatility modules.
Cyclerion | Operating Income |
Latest Cyclerion Therapeutics' Operating Income Growth Pattern
Below is the plot of the Operating Income of Cyclerion Therapeutics over the last few years. Operating Income is the amount of profit realized from Cyclerion Therapeutics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Cyclerion Therapeutics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. Cyclerion Therapeutics' Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cyclerion Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Operating Income | 10 Years Trend |
|
Operating Income |
| Timeline |
Cyclerion Operating Income Regression Statistics
| Arithmetic Mean | (65,313,157) | |
| Coefficient Of Variation | (48.14) | |
| Mean Deviation | 20,563,116 | |
| Median | (63,554,000) | |
| Standard Deviation | 31,441,894 | |
| Sample Variance | 988.6T | |
| Range | 115.4M | |
| R-Value | 0.30 | |
| Mean Square Error | 966.1T | |
| R-Squared | 0.09 | |
| Significance | 0.27 | |
| Slope | 2,139,156 | |
| Total Sum of Squares | 13840.3T |
Cyclerion Operating Income History
Other Fundumenentals of Cyclerion Therapeutics
Cyclerion Therapeutics Operating Income component correlations
Click cells to compare fundamentals
About Cyclerion Therapeutics Financial Statements
Cyclerion Therapeutics investors utilize fundamental indicators, such as Operating Income, to predict how Cyclerion Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Operating Income | -9.6 M | -10.1 M | |
| Non Operating Income Net Other | 529.2 K | 1 M |
Pair Trading with Cyclerion Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cyclerion Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cyclerion Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Cyclerion Stock
| 0.77 | BMY | Bristol Myers Squibb Sell-off Trend | PairCorr |
| 0.73 | VTRS | Viatris | PairCorr |
| 0.69 | ESPR | Esperion Therapeutics Buyout Trend | PairCorr |
| 0.65 | WAT | Waters | PairCorr |
| 0.5 | GILD | Gilead Sciences | PairCorr |
The ability to find closely correlated positions to Cyclerion Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cyclerion Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cyclerion Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cyclerion Therapeutics to buy it.
The correlation of Cyclerion Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cyclerion Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cyclerion Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cyclerion Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Cyclerion Therapeutics Correlation against competitors. To learn how to invest in Cyclerion Stock, please use our How to Invest in Cyclerion Therapeutics guide.You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclerion Therapeutics. If investors know Cyclerion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclerion Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.08) | Revenue Per Share 0.586 | Quarterly Revenue Growth 0.141 | Return On Assets (0.47) | Return On Equity (1.50) |
The market value of Cyclerion Therapeutics is measured differently than its book value, which is the value of Cyclerion that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclerion Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cyclerion Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclerion Therapeutics' market value can be influenced by many factors that don't directly affect Cyclerion Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cyclerion Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cyclerion Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclerion Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.